1322616-36-3

Basic information

• Product Name: 5-Quinolinecarboxylic acid, 7-fluoro-2-(4-fluorophenyl)-1,2,3,4-tetrahydro-3-(1-Methyl-1H-1,2,4-triazol-5-yl)-4-oxo-, Methyl ester
• Synonyms: 5-Quinolinecarboxylic acid, 7-fluoro-2-(4-fluorophenyl)-1,2,3,4-tetrahydro-3-(1-Methyl-1H-1,2,4-triazol-5-yl)-4-oxo-, Methyl ester;Methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-Methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate;Methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydro
• CAS NO: 1322616-36-3
• Molecular Formula: C₂₀H₁₆F₂N₄O₃
• Molecular Weight: 398.3628464
• Mol File: 1322616-36-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 641.4±65.0 °C(Predicted)
• Appearance: /
• Density: 1.47±0.1 g/cm3(Predicted)
• PKA: 2.51±0.10(Predicted)
• CAS DataBase Reference: 5-Quinolinecarboxylic acid, 7-fluoro-2-(4-fluorophenyl)-1,2,3,4-tetrahydro-3-(1-Methyl-1H-1,2,4-triazol-5-yl)-4-oxo-, Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Quinolinecarboxylic acid, 7-fluoro-2-(4-fluorophenyl)-1,2,3,4-tetrahydro-3-(1-Methyl-1H-1,2,4-triazol-5-yl)-4-oxo-, Methyl ester(1322616-36-3)
• EPA Substance Registry System: 5-Quinolinecarboxylic acid, 7-fluoro-2-(4-fluorophenyl)-1,2,3,4-tetrahydro-3-(1-Methyl-1H-1,2,4-triazol-5-yl)-4-oxo-, Methyl ester(1322616-36-3)

Safety Data

• Hazardous Substances Data: 1322616-36-3(Hazardous Substances Data)

Usage

General Description

The chemical 5-Quinolinecarboxylic acid, 7-fluoro-2-(4-fluorophenyl)-1,2,3,4-tetrahydro-3-(1-Methyl-1H-1,2,4-triazol-5-yl)-4-oxo-, Methyl ester is a methyl ester derivative of 7-fluoro-2-(4-fluorophenyl)-1,2,3,4-tetrahydro-3-(1-Methyl-1H-1,2,4-triazol-5-yl)-4-oxo-5-quinolinecarboxylic acid. It is a fluorinated compound with potential antifungal and antineoplastic activities. It is also used as a fluorescent probe and a drug intermediate. Additionally, it may possess other biological activities due to its structure and may have potential applications in pharmaceutical and chemical research.

Upstream product

• 459-57-4 4-fluorobenzaldehyde 
• 1322879-81-1 methyl 5-fluoro-2-(2-(1-methyl-1H-1,2,4-triazol-5-yl)acetyl)-3-nitrobenzoate 
• 1322616-39-6 (E)-methyl 5-fluoro-2-(3-(4-fluorophenyl)-2-(1-methyl-1H-1,2,4-triazol-5-yl)acryloyl)-3-nitrobenzoate 
• 1322616-40-9 methyl 7-fluoro-2-(4-fluorophenyl)-1-hydroxy-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate 
• 1207453-90-4 6-fluoro-4-nitroisobenzofuran-1(3H)-one 
• 1322616-34-1 (Z)-6-fluoro-3-((1-methyl-1H-1,2,4-triazol-5-yl)methylene)-4-nitroisobenzofuran-1(3H)-one 

Downstream Products

• 1207454-56-5 5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one 
• 1207456-01-6 ((11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1,5⁽¹³⁾,6,8-tetraen-4-one) 
• 1207456-00-5 (8R,9S)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3 ,2-de] phthalazin-3(7H)-one 
• 1373329-52-2 (2R,3R)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate 
• 1373329-49-7 CH₄O₃S*C₁₉H₁₄F₂N₆O 
• 1373329-50-0 C₂H₆O₄S*C₁₉H₁₄F₂N₆O 
• 1373329-51-1 C₁₉H₁₄F₂N₆O*H₃O₄P 
• 1373329-48-6 C₁₉H₁₄F₂N₆O*ClH 

Relevant articles and documents

DoE Optimization Empowers the Automated Preparation of Enantiomerically Pure [18F]Talazoparib and its in Vivo Evaluation as a PARP Radiotracer

Given the clinical potential of poly(ADP-ribose) polymerases (PARP) imaging for the detection and stratification of various cancers, the development of novel PARP imaging probes with improved pharmacological profiles over established PARP imaging agents i

DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) FOR THE TREATMENT OF MULTIPLE MYELOMA

Provided is a methods of treating multiple myeloma with inhibitors of poly(ADP-ribose)polymerase according to Formula (I):

PROCESSES OF SYNTHESIZING DIHYDROPYRIDOPHTHALAZINONE DERIVATIVES

Provided herein are processes for synthesizing dihydropyridophthalazinone derivatives, such as for example, 5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one and its stereoisomers, which are potent poly(ADP-ribose)polymerase (PARP) inhibitors as well as novel synthetic intermediate compounds.